Close Menu

GenMark

Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased. 

GenMark said it intends to use the proceeds for general corporate purposes that may include an expansion of its menu and increasing its manufacturing capacity.

The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.

Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.

Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said

Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.

The firm now expects to complete the development work needed to request Emergency Use Authorization for the new panel.

Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.

The ePlex SARS-CoV-2 Test is exclusively for use on the company's ePlex sample-to-answer system, which has a global installed base of more than 500 as of the end of 2019.

The partners' "COVID-19 task force" will invest in ePlex molecular testing platforms from GenMark Diagnostics to quadruple UCSF's testing capacity.

Pages